Body Pharm TB-500 10mg is a lyophilised thymosin beta-4 fragment (Ac-LKKTETQ) supplied in single 10 mg vials for in vitro research use, sold into the South African research market alongside companion peptides such as BPC-157. This page consolidates what local procurement officers need: mechanism-of-action context (2025–2026), a TB-500 + BPC-157 dual-peptide protocol framework, ZAR pricing context, and cold-chain handling notes calibrated to South African laboratory conditions. You will find TB-500's actin-binding and angiogenic pathways covered below, along with how to reconstitute and store the peptide safely during load-shedding, and how to pair it with BPC-157 in tissue-repair assays. Last updated: May 2026.
Key Takeaways
- TB-500 is the synthetic acetylated heptapeptide Ac-LKKTETQ (amino acids 17–23 of Thymosin Beta-4), supplied at ≥98% purity for in vitro research only
- The peptide operates through G-actin sequestration, VEGF-mediated angiogenesis, and NF-κB suppression; no completed human randomised controlled trials exist as of May 2026
- TB-500 and BPC-157 are paired in research designs because they act on non-overlapping pathways, enabling additive effects in scratch-assay and tubule-formation models
- Reconstituted TB-500 remains stable for 28 days at 2–8 °C; load-shedding cold-chain risk requires UPS backup and passive holdover capacity in South African labs
- Procurement officers must verify Section 21 authorisation or equivalent research permit status with SAHPRA before ordering unregistered research peptides
What this overview covers
A 2024 review in PMC on local and systemic peptide therapies for soft tissue regeneration remains the most current peer-reviewed source for TB-500's actin-binding and angiogenic pathways. The sections below pair that evidence base with sourcing, reconstitution, and shipping considerations specific to researchers operating in Johannesburg, Cape Town, Durban, and Pretoria.
What Is TB-500? The Thymosin Beta-4 Fragment Explained
TB-500 is the synthetic acetylated heptapeptide Ac-LKKTETQ, corresponding to amino acids 17–23 of Thymosin Beta-4 (the TMSB4X gene product), with a molecular weight of approximately 807 Da. It is not the full 43-residue Thymosin Beta-4 protein but the actin-sequestering domain responsible for the majority of TB4's documented biological activity in cell culture models.
The distinction matters for procurement records. Endogenous Thymosin Beta-4 is a naturally occurring polypeptide expressed across mammalian tissues. The Human Protein Atlas shows highest TMSB4X expression in platelets and cardiac tissue. The synthetic research peptide sold as TB-500 reproduces only the active fragment, which simplifies solid-phase synthesis and gives a more consistent reference material for in vitro work.
Regulatory status and intended use
Body Pharm TB-500 10mg is supplied strictly for in vitro and preclinical research. It is not approved for human or veterinary use by the South African Health Products Regulatory Authority (SAHPRA) or any equivalent regulator, and no clinical efficacy or safety claims are made on this page. Researchers ordering the 10 mg vial accept responsibility for compliant handling within their institution's research governance framework.
For laboratories building wider repair-pathway protocols, the peptides catalogue lists companion fragments including BPC-157, while IGF-1 LR3 is frequently incorporated into satellite cell and myogenic differentiation models alongside TB-500.
Body Pharm TB-500 10mg: Product Specifications
The Body Pharm TB-500 10mg vial is a lyophilised acetylated heptapeptide (Ac-LKKTETQ) supplied at ≥98% purity by HPLC (High-Performance Liquid Chromatography), manufactured by Body Pharm and distributed locally in South Africa through JCSG.org. The specifications below reflect the standard research-grade format used in in vitro tissue-repair assays.
| Specification | Value |
|---|---|
| Peptide name | TB-500 (Thymosin Beta-4 fragment 17–23) |
| Sequence | Ac-LKKTETQ |
| CAS number | 77591-33-4 |
| Vial size | 10 mg |
| Form | Lyophilised white powder |
| Purity | ≥98% by HPLC |
| Molecular formula | C₃₈H₆₈N₉O₁₂ |
| Molecular weight | ~861 Da |
| Recommended solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Manufacturer | Body Pharm |
| Local distributor | JCSG.org |
The 10 mg format is more practical for multi-assay or multi-timepoint research designs than 5 mg vials. Reconstituted at 1 mg/mL in 10 mL bacteriostatic water, a single vial yields up to 20 × 500 µg aliquots, enough to cover dose-response curves across 96-well plate replicates without splitting work over two reconstitution events. Fewer reconstitutions mean fewer septum punctures, lower contamination risk, and a tighter chain of custody for batch records.
For protocols pairing TB-500 with companion fragments, the BPC-157 research peptide listing covers the standard co-administered cytoprotective peptide, and IGF-1 LR3 is the usual third component in satellite-cell and myogenic differentiation models.
Mechanism of Action: How TB-500 Works In Vitro
TB-500 acts in cell culture through three investigated pathways: G-actin sequestration that enables cytoskeletal remodelling, VEGF (Vascular Endothelial Growth Factor)-mediated angiogenic signalling, and downregulation of NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) inflammatory markers. All current mechanistic evidence as of May 2026 derives from in vitro assays and rodent models; no completed human randomised controlled trials exist for the Ac-LKKTETQ fragment.
G-actin sequestration and cell migration
TB-500 binds monomeric (G-) actin because the central KLKKTET motif of the parent thymosin beta-4 molecule is retained in the fragment. This binding modulates the G-actin/F-actin equilibrium that governs lamellipodial extension. In scratch-wound and Boyden-chamber assays, the result is accelerated fibroblast and endothelial cell migration into the cell-free zone. Researchers building migration assays around the BPC-157 research peptide catalogue typically use TB-500 as the actin-modulating arm of a dual-peptide design.
VEGF upregulation and angiogenic sprouting
TB-500 upregulates VEGF expression in endothelial cell culture by activating AKT-linked pro-angiogenic transcription, which drives tubule formation in Matrigel assays. The Goldstein & Kleinman characterisation of this pathway is now over a decade old and should be cross-checked against more recent replications before being cited as current. The 2024 review on local and systemic peptide therapies for soft tissue regeneration summarises the angiogenic literature but does not itself constitute a new primary VEGF assay. For satellite-cell and myogenic models where VEGF and IGF signalling converge, IGF-1 LR3 is the conventional co-treatment.
NF-κB suppression in inflammatory models
TB-500 attenuates NF-κB pathway activity in macrophage and soft-tissue models because thymosin beta-4-derived fragments interfere with upstream IκB kinase signalling, reducing downstream TNF-α and IL-6 transcription. The magnitude of suppression reported in the available 2024 review is model-dependent and has not been quantified in a SAHPRA-recognised human trial as of May 2026.
TB-500 + BPC-157 Dual-Peptide Research Protocol (2026)
TB-500 and BPC-157 are paired in research designs because they act on non-overlapping pathways. TB-500 modulates G-actin sequestration and VEGF-linked angiogenesis; BPC-157 (a 15-amino-acid pentadecapeptide) operates primarily through nitric oxide signalling and growth hormone receptor upregulation. The complementary mechanisms motivate combined scratch-assay and tubule-formation designs rather than redundant single-target work.
I treat the framework below as a literature-derived starting point for in vitro work, not a clinical dosing guide. No SAHPRA-recognised human protocol exists for either peptide as of May 2026, and no peer-reviewed 2024–2026 in vitro paper in the verified source set documents an exact combined TB-500 + BPC-157 concentration matrix. Researchers locating BPC-157 stock should consult the BPC-157 research peptide catalogue entry; for satellite-cell co-treatment work, IGF-1 LR3 is the conventional third arm.
Protocol framework table
| Peptide | Concentration range (in vitro) | Vehicle | Co-administration timing | Observed endpoint |
|---|---|---|---|---|
| TB-500 | 50–200 ng/mL | DMEM + 0.1% BSA | Added at t = 0 | Actin cytoskeletal priming, lamellipodial extension |
| BPC-157 | 1–10 µg/mL | DMEM + 0.1% BSA | Added at t = +30 min | NO-mediated migration, scratch closure |
| Combined | TB-500 100 ng/mL + BPC-157 10 µg/mL | DMEM + 0.1% BSA | Sequential, 30-min offset | Additive scratch-wound closure vs. monotherapy |
Order of addition
I add TB-500 first to allow approximately 30 minutes of cytoskeletal priming before BPC-157 is introduced. The rationale is mechanistic sequencing: actin remodelling precedes the nitric oxide-dependent migratory response. Simultaneous addition risks masking the additive effect that sequential dosing exposes in scratch assays. Run a vehicle-only control plate and single-peptide arms in parallel to isolate the combination effect.
Reconstitution, Storage & Handling in South African Labs
Reconstitute the 10 mg lyophilised vial with 2–3 mL of bacteriostatic water (0.9% benzyl alcohol in sterile water for injection), sourced from South African pharmacy wholesalers such as Dis-Chem or Medirite. Wipe the rubber stopper with 70% isopropanol, inject the diluent slowly down the inner vial wall, then swirl gently until the cake dissolves. Do not vortex or shake: TB-500 is a 43-residue peptide and mechanical shear can fragment it.
Storage parameters
Store lyophilised vials at −20 °C in a standard lab freezer. After reconstitution, hold the working solution at 2–8 °C and use within 28 days. Lyophilised peptides held at −20 °C typically lose under 2% purity per year, whereas room-temperature storage degrades reconstituted material substantially faster because peptide degradation accelerates above 25 °C. This is a real constraint: Gauteng, KwaZulu-Natal, and Western Cape summer ambient temperatures routinely exceed 35 °C.
Load-shedding cold-chain mitigation
Eskom load-shedding remains the dominant cold-chain risk for South African research labs in 2026. Stage 4–6 schedules can produce refrigerator excursions sufficient to compromise reconstituted aliquots over a single working day. I run our 2–8 °C fridge on a UPS (Uninterruptible Power Supply) sized for at least four hours. I keep a sealed polystyrene box with pre-frozen gel packs as a passive holdover, and maintain a dry-ice contingency for outages beyond six hours. Aliquot the reconstituted solution into single-use volumes immediately after reconstitution to avoid repeated warm-up cycles. Log fridge min/max temperatures with a calibrated data logger.
Researchers running parallel arms can locate companion peptides via the BPC-157 research peptide catalogue or the IGF-1 LR3 entry for satellite-cell co-treatment work.
Shipping & Ordering TB-500 10mg in South Africa
Order Body Pharm TB-500 10mg via JCSG.org (jcsg.org/za) through a secure checkout with ZAR pricing displayed on the product page and discreet tracked courier delivery to most metros. Pricing changes, so confirm the live figure at checkout rather than relying on cached values.
Material ships as a research chemical for in vitro use only. South African importation of unregistered substances falls under the Medicines and Related Substances Act 101 of 1965 (as amended). Institutional procurement officers should verify their Section 21 authorisation or equivalent research permit status with SAHPRA before placing orders. Lyophilised TB-500 is comparatively stable in transit, but for summer dispatches between November and February I request cold-pack insulation to keep vials below 25 °C through the courier leg, particularly for inland deliveries crossing Gauteng heat.
Companion peptides in the same order
Researchers running dual-peptide protocols typically add a BPC-157 research peptide to the same consignment, and satellite-cell co-treatment arms often include IGF-1 LR3 for parallel comparison.
Related Research Peptides Available in South Africa
Researchers investigating TB-500 are often sourcing complementary peptides for parallel pathway studies on the same purchase order. The most common co-investigations in the 2023–2024 satellite-cell and tissue-repair literature pair TB-500 with IGF-1 LR3 for growth-factor signalling comparisons, and with BPC-157 for cytoprotective overlap.
GHK-Cu, the copper-binding tripeptide, draws interest from groups studying extracellular matrix remodelling and VEGF-mediated angiogenesis, mechanistic territory it shares with TB-500's actin-sequestering role in endothelial migration models. Epithalon appears in telomere-length and senescence research arms, while the Ipamorelin/CJC-1295 combination is sourced by labs modelling the GH (Growth Hormone) secretagogue axis as an upstream variable in repair studies.
The full BPC-157 research peptide catalogue and adjacent compounds are indexed on JCSG.org for procurement officers building multi-arm protocols from a single supplier.
Frequently Asked Questions: TB-500 Research Peptide SA
What is the difference between TB-500 and Thymosin Beta-4?
TB-500 is a synthetic fragment (Ac-LKKTETQ) of the full 43-amino-acid Thymosin Beta-4 (TB4) protein. The fragment retains the actin-binding and cell-migration activity attributed to the parent peptide in soft-tissue regeneration research. It is shorter, cheaper to synthesise, and easier to reconstitute for in vitro work.
Is TB-500 legal to purchase in South Africa for research?
The SAHPRA classification and Section 21 import pathway for unregistered research peptides such as TB-500 in 2026 is from the sources reviewed. Procurement officers should confirm the current scheduling status and any Section 21 authorisation requirements directly with SAHPRA before placing an order intended for laboratory use.
What purity should research-grade TB-500 have?
Research-grade TB-500 should be ≥98% pure by HPLC, the accepted benchmark for synthetic peptides used in in vitro assays. A batch-specific certificate of analysis stating purity, residual solvents, endotoxin (EU/mg), and mass-spec confirmation should accompany every 10 mg vial sourced from Body Pharm or any other supplier.
Can TB-500 and BPC-157 be reconstituted in the same vial?
Co-reconstitution is not recommended. Reconstitute TB-500 and BPC-157 separately in bacteriostatic water so each peptide's concentration can be controlled independently across assay arms. Separate reconstitution also prevents the degradation kinetics of one compound from confounding the other in stability sampling.
How long does TB-500 remain stable after reconstitution?
Reconstituted TB-500 is typically stable for 28 days at 4 °C when stored in bacteriostatic water, consistent with ICH (International Council for Harmonisation) Q1A-aligned guidance for lyophilised peptides. For longer holds, aliquot and store at −20 °C to avoid freeze-thaw cycles, which degrade the peptide and confound results in repeat-measure designs alongside IGF-1 LR3 comparators.
Next Steps
Confirm your institution's Section 21 authorisation status with SAHPRA, then add Body Pharm TB-500 10mg to your research order via the secure checkout on the JCSG.org product page. Include BPC-157 and IGF-1 LR3 in the same consignment if you are running dual- or triple-peptide protocols, and request cold-pack insulation for summer delivery.
